BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coyle PK, Gocke A, Vignos M, Newsome SD. Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era. Adv Ther 2021;38:3550-88. [PMID: 34075554 DOI: 10.1007/s12325-021-01761-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Kong L, Wang X, Chen H, Shi Z, Lang Y, Zhang Y, Zhou H. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis. Mult Scler Relat Disord 2022;68:104167. [PMID: 36170773 DOI: 10.1016/j.msard.2022.104167] [Reference Citation Analysis]
2 Tondo G, Virgilio E, Naldi A, Bianchi A, Comi C. Safety of COVID-19 Vaccines: Spotlight on Neurological Complications. Life 2022;12:1338. [DOI: 10.3390/life12091338] [Reference Citation Analysis]
3 Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol Rev 2022. [PMID: 35661178 DOI: 10.1111/imr.13091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
4 Lucchini M, Del Giacomo P, De Arcangelis V, Nociti V, Bianco A, De Fino C, Presicce G, Cicia A, Carlomagno V, Mirabella M. The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre. JPM 2022;12:591. [DOI: 10.3390/jpm12040591] [Reference Citation Analysis]
5 Krzystanek E, Jurczak A, Kocur K, Jurkiewicz J, Kaczmarczyk A. Awareness of COVID-19 Symptoms, Risk Factors, and Vaccinations in Patients with Multiple Sclerosis. IJERPH 2022;19:3366. [DOI: 10.3390/ijerph19063366] [Reference Citation Analysis]
6 Fragoso YD, Gomes S, Gonçalves MVM, Mendes Junior E, Oliveira BES, Rocha CF, Santos GACD, Tauil CB, Araujo RV, Peron JPS. New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19. Mult Scler Relat Disord 2022;57:103321. [PMID: 35158439 DOI: 10.1016/j.msard.2021.103321] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
7 Kantarcioglu B, Iqbal O, Lewis J, Carter CA, Singh M, Lievano F, Ligocki M, Jeske W, Adiguzel C, Gerotziafas GT, Fareed J. An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clin Appl Thromb Hemost 2022;28:107602962110566. [DOI: 10.1177/10760296211056648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Golshani M, Hrdý J. Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination. Vaccines 2022;10:279. [DOI: 10.3390/vaccines10020279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Kataria S, Rogers S, Bilal U, Baktashi H, Singh R. Multiple Sclerosis Relapse Following COVID-19 Vaccination: A Case Report and Literature Review. Cureus 2022. [DOI: 10.7759/cureus.21374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cohen JA, Bermel RA, Grossman CI, Hersh CM, Hyland M, Mowry EM, Naismith R, Naylor ML, Nicholas J, Rajbhandar R, Singh CM, Tintorè M, Zabalza A, Ziemssen T, Williams JR, Montalban X. Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Mult Scler 2022;:13524585211061343. [PMID: 34994577 DOI: 10.1177/13524585211061343] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Maple PAC. Multiple Sclerosis, Viruses, and New Vaccines. Neurol Int 2021;13:712-4. [PMID: 34940754 DOI: 10.3390/neurolint13040068] [Reference Citation Analysis]
12 Nistri R, Barbuti E, Rinaldi V, Tufano L, Pozzilli V, Ianniello A, Marinelli F, De Luca G, Prosperini L, Tomassini V, Pozzilli C. Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases. Front Neurol 2021;12:765954. [PMID: 34744992 DOI: 10.3389/fneur.2021.765954] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
13 Michiels Y, Houhou-Fidouh N, Collin G, Berger J, Kohli E. Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient. Vaccines (Basel) 2021;9:1140. [PMID: 34696248 DOI: 10.3390/vaccines9101140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Chaudhary S, El-shorbagi A, Gupta RK, Kumar A. The Recent Updates on Approaches and Clinical Trials Status of Covid-19 Vaccines Developed Globally. Biomed Pharmacol J 2021;14:1109-24. [DOI: 10.13005/bpj/2214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Yamout BI, Zakaria M, Inshasi J, Al-Jumah M, Zeineddine M, Dahdaleh M, Bohlega S, Gouider R, Alroughani R. MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. Mult Scler Relat Disord 2021;56:103225. [PMID: 34479111 DOI: 10.1016/j.msard.2021.103225] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]